Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study

Table 1 Comparison of demographic variables and clinical outcomes between PRIS and non-PRIS patients

	PRIS n = 11	No PRIS n = 1006	P value
Age (years)^A	58 ± 14	56 ± 18	0.64
Male (%)	82	65	0.4
APACHE II score^A	25 ± 6	20 ± 6	0.03
Admitting service (%)
Medicine	36	35	0.82
Surgery
Neurosurgery	9	25	0.39
Trauma	9	23	0.47
Other surgery	46	17	0.04
Primary reason for ICU admit (%)
Trauma	18	23	1.0
Surgery	28	21	0.89
Neurological	9	20	0.6
Respiratory failure	36	17	0.2
Cardiac	0	9	0.61
Other	9	10	0.77
Past medical history (%)
Coronary artery disease	27	30	0.89
Malignancy	36	18	0.24
Congestive heart failure	18	18	0.71
Diabetes	18	16	0.83
Chronic obstructive pulmonary disease	27	10	0.12
Other	9	12	0.87
Use of propofol dose >83 μg/kg/min (%)	18	10	0.68
Duration of propofol (days)^B	5 (3-7)	4 (3-7)	0.43
Number of PRIS clinical manifestations^C	5 (2-7)	1 (0-6)	0.0001
Duration of ICU stay (days)^B	14 (10-18)	12 (7-20)	0.4
ICU mortality (%)	18	20	0.82
Hospital mortality (%)	18	21	0.88

APACHE = acute physiology and chronic health evaluation; ICU = intensive care unit; PRIS = propofol-relation infusion syndrome.
^AMean ± standard deviation
^BMedian (interquartile range)
^CMedian (Range)

ISSN: 1364-8535